Drug Trial Radar · NCT07077252
Phase I/II Study of SCTB39G in Advanced Solid Tumours
Last checked: Nov 19, 2026Latest source record: Jul 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jul 28, 2025
Primary completion
Sep 26, 2027
Study completion Oct 17, 2027
Sponsor
- Lead sponsor
- Sinocelltech Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB39G as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.
Conditions
- Advanced Malignant Solid Tumor
Interventions
SCTB39GDrug
SCTB39G,IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting toxicity(DLT)Time frame: From Day 0 up to Day 21
- Objective response rate (ORR)Time frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.